Orthofix Medical stock reports USD 210.93 million revenue

Published on 09/30/2026 at 07:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Orthofix Medical stock carries a USD 13.00 Stifel target after Q2 revenue reached USD 210.93 million. Adjusted EPS was minus USD 0.39 versus a USD 0.40 forecast.

OFIX, US6875231068, Illustration mit AI erstellt.

Orthofix Medical stock carries a USD 13.00 Stifel price target after the company reported second-quarter 2026 revenue of USD 210.93 million. Investing.com reported on September 15, 2026, that Stifel maintained its Buy rating and kept the target unchanged.

Revenue beats the quarterly forecast

Orthofix reported Q2 2026 adjusted EPS of minus USD 0.39, compared with the USD 0.40 loss expected by analysts. Revenue of USD 210.93 million exceeded the USD 209.28 million forecast, a USD 1.65 million difference.

The company also raised its full-year 2026 sales and adjusted EBITDA guidance after sales trends improved and a Medicare reimbursement benefit returned, according to Investing.com. The Q2 report covered the period ended June 30, 2026.

Medical device segments show mixed signals

Global limb reconstruction grew 11 percent in Q2 2026, while the therapeutic solutions business benefited from the removal of a reimbursement headwind. Biologics stabilized year over year, but smaller U.S. spine distributors continued to weigh on the operating picture.

That combination matters for the turnaround case: the quarterly loss narrowed against consensus, yet the company still reported GAAP net loss of USD 15.8 million and an operating margin of minus 4.00 percent in Q2 2026. The figures show progress in demand and reimbursement, while profitability remains the central execution test.

Stifel target stays above the market value

Stifel cited profitable growth, commercial execution and the 7D FLASH product as reasons for its rating, according to Investing.com on September 15, 2026. The same report identified essential tremor opportunities and encouraging surgeon checks in limb reconstruction as supporting factors.

Market value remains below yearly high

Orthofix Medical had a market capitalization of USD 394.1 million on September 29, 2026. Its 52-week range was USD 8.50 to USD 16.99, placing the market value against a high that was USD 7.24 above the latest USD 9.75 primary-market quote.